Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 26;11(15):4325.
doi: 10.3390/jcm11154325.

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Tzu-Chen Lo  1   2   3 , Yu-Yen Chen  3   4   5   6   7 , Man-Chen Hung  1   8 , Pesus Chou  9
Affiliations
Review

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Tzu-Chen Lo et al. J Clin Med. .

Abstract

Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.

Keywords: latanoprostene bunod; meta-analysis; ocular hypertension; open-angle glaucoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study retrieval process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
Figure 2
Figure 2
The overall effect of latanoprostene bunod on intraocular pressure.
Figure 3
Figure 3
Comparison of IOP-lowering effect between latanoprostene bunod 0.024% and timolol maleate 0.5%.
Figure 4
Figure 4
Comparison of IOP-lowering effects of latanoprostene bunod 0.024% and latanoprost 0.005%.
Figure 5
Figure 5
Funnel plots evaluating the publication biases regarding the IOP-lowering impacts of (a) LBN 0.024%; (b) the comparison between LBN 0.024% and timolol maleate 0.5%; and (c) the comparison between LBN 0.024% and latanoprost 0.005%. Circles represented studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch. Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268. - DOI - PubMed
    1. Leske M.C., Heijl A., Hussein M., Bengtsson B., Hyman L., Komaroff E. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol. 2003;121:48–56. doi: 10.1001/archopht.121.1.48. - DOI - PubMed
    1. Prum B.E., Jr., Lim M.C., Mansberger S.L., Stein J.D., Moroi S.E., Gedde S.J., Herndon L.W., Jr., Rosenberg L.F., Williams R.D. Primary open-angle glaucoma suspect preferred practice pattern® guidelines. Ophthalmology. 2016;123:P112–P151. doi: 10.1016/j.ophtha.2015.10.055. - DOI - PubMed
    1. Li T., Lindsley K., Rouse B., Hong H., Shi Q., Friedman D.S., Wormald R., Dickersin K. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016;123:129–140. doi: 10.1016/j.ophtha.2015.09.005. - DOI - PMC - PubMed
    1. Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G., Amalfitano F., Anand N., Azuara-Blanco A., Bourne R.R., Broadway D.C., Cunliffe I.A., et al. Latanoprost for open-angle glaucoma (ukgts): A randomised, multicentre, placebo-controlled trial. Lancet. 2015;385:1295–1304. doi: 10.1016/S0140-6736(14)62111-5. - DOI - PubMed

LinkOut - more resources